Show simple item record

dc.contributor.authorDzitko, Katarzyna
dc.contributor.authorPaneth, Agata
dc.contributor.authorPlech, Tomasz
dc.contributor.authorPawełczyk, Jakub
dc.contributor.authorWęglińska, Lidia
dc.contributor.authorPaneth, Piotr
dc.date.accessioned2016-02-09T07:34:21Z
dc.date.available2016-02-09T07:34:21Z
dc.date.issued2014
dc.identifier.citationAntimicrobial Agents and Chemotherapy, Vol. 58, Issue 12, pages 7583-7585
dc.identifier.urihttp://hdl.handle.net/11652/1149
dc.identifier.urihttp://aac.asm.org/content/58/12/7583.full.pdf+html
dc.description.abstractThis article reports anti-Toxoplasma gondii activity of 3-(thiophen-2-yl)-1,2,4-triazole-5-thione. The compound displayed significant and reproducible antiparasitic effects at nontoxic concentrations for the host cells, with an experimentally determined 50% inhibitory concentration (IC50) at least 30 times better than that of the known chemotherapeutic agent sulfadiazine. Purine nucleoside phosphorylase was defined as the probable target for anti-Toxoplasma activity of the tested compound. These results provide the foundation for future work to develop a new class of medicines to better treat toxoplasmosis.en_EN
dc.language.isoenen_EN
dc.relation.ispartofseriesAntimicrobial Agents and Chemotherapy, Vol. 58, Issue 12, 2014en_EN
dc.titleTriazole-Based Compound as a Candidate To Develop Novel Medicines To Treat Toxoplasmosisen_EN
dc.typeArtykułpl_PL
dc.typeArticleen_EN


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record